title: Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects.
abstract: Thiazolidinedione (TZD) compounds enhance insulin sensitivity and attenuate inflammation. The effect of the TZD compound, rosiglitazone (RSG) on both actions was evaluated in two groups of insulin-resistant subjects with minimal elevations of fasting plasma glucose (PG) concentration: group A (n=15, PG < 7.0 mmol/L) and group B (n=14, PG 7.0-8.3 mmol/L). Insulin action, quantified by the insulin suppression test, improved after three months of treatment in both groups, and concentrations of C-reactive protein, plasminogen activator inhibitor-1 and Eselectin all fell. Significant decreases in L-selectin and P-selectin were confined to group B, and concentrations of interleukin-6, intercellular adhesion molecule-1 and vascular cellular adhesion molecule-1 did not fall in either group. Significant relationships were not discerned between enhanced insulin sensitivity and related variables and decreases in inflammatory/vascular markers, suggesting that RSG-induced changes in the latter variables in insulin-resistant individuals might be at least partly independent of the effects of the drug on insulin action.
authors.affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, California, 94305, USA.
authors.forename: James W
authors.initials: JW
authors.lastname: Chu
authors.forename: Fahim
authors.initials: F
authors.lastname: Abbasi
authors.forename: Cynthia
authors.initials: C
authors.lastname: Lamendola
authors.forename: Tracey
authors.initials: T
authors.lastname: McLaughlin
authors.forename: Gerald M
authors.initials: GM
authors.lastname: Reaven
authors.forename: Philip S
authors.initials: PS
authors.lastname: Tsao
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001786:Blood Glucose; D002097:C-Reactive Protein / Q000032:analysis; D015815:Cell Adhesion Molecules / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004730:Endothelium, Vascular / Q000187:drug effects; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007249:Inflammation / Q000097:blood / Q000188:drug therapy; D018836:Inflammation Mediators / Q000097:blood; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D000077154:Rosiglitazone; D019087:Selectins / Q000097:blood; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D001786:Blood Glucose; D015815:Cell Adhesion Molecules; D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D018836:Inflammation Mediators; D007328:Insulin; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D019087:Selectins; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D002097:C-Reactive Protein